… ProQR Announces Results for the First Quarter of 2017 Key … Investigational new drug (IND) application for QR-110, ProQR’s lead program in ophthalmology, was cleared by the FDA … Usher syndrome. The Company announced that it will host an R&D Day on June 15 th in New York where Company executives …
… ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory … a key strategic role in the development and advancement of ProQR’s growing ophthalmology pipeline. LEIDEN, The … chaired by Gerard Platenburg, Chief Innovation Officer of ProQR, now consists of six members including: Drs. Art Levin, …
… ProQR Announces Third Quarter 2021 Operating and Financial … with Lilly highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens … Officer,” said Daniel A. de Boer, Founder and CEO of ProQR. “Theresa is a seasoned leader with deep rare disease …
… ProQR Announces Third Quarter 2024 Operating and Financial … & CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company … approximately $82.1 million. Research and development (R&D) costs were €9.4 million for the quarter ended September …
… ProQR Announces First Quarter 2021 Operating and Financial … & CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … for the same period last year. Research and development (R&D) costs were €8.9 million for the quarter ended March 31, …
LEIDEN, the Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Company will present at two investor conferences during the month of September. Cantor Fitzgerald Global Healthcare Conference
… ProQR Announces Second Quarter 2022 Operating and Financial … CNS therapeutic areas, which have strong alignment with ProQR’s oligonucleotide delivery approaches. The Company will … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …